Please wait while the formulary information is being retrieved.
LORZONE (CHLORZOXAZONE)
- Muscle spasm
375 mg tablet
- 1 tablet (375 mg) by oral route 3 times per day
750 mg tablet
- 1 tablet (750 mg) by oral route 3 times per day
Muscle spasm
- 1 tablet (375 mg) by oral route 3 times per day
- 1 tablet (375 mg) by oral route 4 times per day
- 2 tablets (750 mg) by oral route 3 times per day
- 2 tablets (750 mg) by oral route 4 times per day
- 1 tablet (750 mg) by oral route 3 times per day
- 1 tablet (750 mg) by oral route 4 times per day
- None
Contraindicated
- sodium oxybate
- Xyrem
Severe
Moderate
- Juxtapid
- lomitapide
- Drug-induced hepatitis
Contraindicated
- Abnormal hepatic function tests
Severe
Moderate
- None
LORZONE (CHLORZOXAZONE)
- Muscle spasm
- None
- Dizziness
- Drowsy
More Frequent
Severe
Less Severe
- None
- Constipation
- Diarrhea
- Gastrointestinal irritation
- Headache disorder
- Heartburn
- Malaise
- Nausea
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Agranulocytosis
- Allergic dermatitis
- Anaphylaxis
- Anemia
- Angioedema
- Drug-induced hepatitis
- Gastrointestinal hemorrhage
- Pruritus of skin
- Skin rash
- Urticaria
Less Severe
- Acute confusion
- Ecchymosis
- Memory impairment
- Paresthesia
- Petechiae
- Urine discoloration
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Chlorzoxazone
- Severity Level:
C
- Additional Notes:
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Chlorzoxazone
Insuff data avail. molecular wt low enough for possible breastmilk excretion
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insuff data avail. molecular wt low enough for possible breastmilk excretion |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Chlorzoxazone
Neuro/Psych-May cause sedation, worsen cognitive impairment and increase fall risk.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | Y | N | Y | N | N |
BEERS: Y HEDIS: Y STOPP: N
No Known Risk
None
- None
| Muscle spasm | |
| M62.83 | Muscle spasm |
| M62.830 | Muscle spasm of back |
| M62.831 | Muscle spasm of calf |
| M62.838 | Other muscle spasm |
| R25.2 | Cramp and spasm |
| 0-9 | A-Z |
|---|---|
| M62.83 | Muscle spasm |
| M62.830 | Muscle spasm of back |
| M62.831 | Muscle spasm of calf |
| M62.838 | Other muscle spasm |
| R25.2 | Cramp and spasm |
Formulary Reference Tool